

PATENT

14102-1US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	Group Art Unit: To be assigned
)	
ESCHER, Alan P. et al.)	Examining Attorney: To be assigned
)	
Serial No.: To be assigned)	
)	
Filed: February 4, 2005)	
)	
For: Substances for Preventing and)	
Treating Autoimmune Diseases)	Pasadena, California

STATEMENT IN ACCORDANCE WITH 37 CFR 1.821(c) and (e)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Enclosed with this Statement in the above-identified United States application is a Sequence Listing and a computer readable form of the sequence listing filed herewith in accordance with 37 CFR 1.821(c) and (e).

37 CFR 1.821(f) - I hereby state that the content of the paper and computer readable copies of the Sequence Listing submitted herewith in accordance with 37 CFR 1.821(c) and (e), respectively, are the same.

10/523655

DT12 Rec'd PCT/PTO 04 FEB 2005

PATENT

14102-1US

No fee is believed due with this Communication. However, the Commissioner is hereby authorized to charge payment of any fees associated with this Communication to Deposit Account No. 19-2090.

Respectfully submitted,

SHELDON & MAK PC

Date: February 4, 2005

By: David Farah
David A. Farah, M.D.
Reg. No. 38,134

Sheldon & Mak PC
A Professional Corporation
225 South Lake Avenue, 9th Floor
Pasadena, CA 91101
Tel.: (626) 796-4000
Fax: (626) 795-6321